Stiffening of large arteries, clinically manifesting as increased aortic pulse wave velocity (PWV), is an inevitable outcome of aging. Among other mechanisms, impaired glucose metabolism plays an important role, leading to the deposition of advanced glycation end products (AGEs). This process is counterbalanced by the circulating soluble receptor for AGEs (sRAGE). We investigated the association between arterial stiffness on one side and multiple circulating biomarkers and the degree of skin deposition of AGEs on the other. In a cross-sectional design, 867 participants based on a general population sample (Czech post-MONICA studies) were examined. PWV was measured by SphygmoCor device (AtCor Medical Ltd.), while skin AGEs were measured using a dedicated autofluorescence method (AGE Reader mu®). To quantify the circulating status of AGEs, carboxymethyl lysine (CML) and sRAGE concentrations were assessed by ELISA, along with conventional glucose metabolism indicators. When analyzing the whole sample using multiple linear or logistic regression models and after adjustment for potential covariates, a significant association with PWV was found for fasting glycemia, HbA1c, sRAGE, skin AGEs, and the skin AGE-to-sRAGE ratio. Among these parameters, stepwise models identified the strongest association for the skin AGEs and AGE-to-sRAGE ratio, and this was also true when diabetic subjects were excluded. In contrast, neither CML nor its ratio relative to sRAGE showed any association with arterial stiffness. In conclusion, skin AGEs along with their ratio relative to sRAGE were closely associated with arterial stiffness and is a better indicator of the current status of deposited AGEs than other relevant factors.

2nd Department of Internal Medicine Medical Faculty of Charles University and University Hospital Pilsen Czech Republic

Biomedical Center Medical Faculty of Charles University Pilsen Czech Republic

Centre for Cardiovascular Prevention of the 1st Faculty of Medicine Charles University and Thomayer Hospital Prague Czech Republic

Department of Clinical Biochemistry and Hematology University Hospital Pilsen Czech Republic

Zobrazit více v PubMed

O’Rourke MF, Mancia G. Arterial stiffness. J Hypertens. 1999;17:1–4. PubMed DOI

Robert L. Aging of the vascular-wall and atherosclerosis. Exp Gerontol. 1999;34:491–501. PubMed DOI

Folkow B, Svanborg A. Physiology of cardiovascular aging. Physiol Rev. 1993;73:725–64. PubMed DOI

Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension. 2009;54:1328–36. PubMed DOI

Collaboration TRVfAS. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J. 2010;31:2338–50. DOI

Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318–27. PubMed DOI

Herbert A, Cruickshank JK, Laurent S, Boutouyrie P. Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. Eur Heart J. 2014;35:3122–33. PubMed DOI

Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114:597–605. PubMed DOI

Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Investig. 1997;99:457–68. PubMed DOI PMC

Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44:129–46. PubMed DOI

Kalousova M, Zima T, Tesar V, Dusilova-Sulkova S, Skrha J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res. 2005;579:37–46. PubMed DOI

Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis. 2008;196:9–21. PubMed DOI

Georgianos PI, Pikilidou MI, Liakopoulos V, Balaskas EV, Zebekakis PE. Arterial stiffness in end-stage renal disease-pathogenesis, clinical epidemiology, and therapeutic potentials. Hypertens Res. 2018;41:309–19. PubMed DOI

Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YCE, et al. Cloning and expression of a cell-surface receptor for advanced glycosylation end-products of proteins. J Biol Chem. 1992;267:14998–5004. PubMed DOI

Vasan S, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature. 1996;382:275–8. PubMed DOI

Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med. 2007;13:625–35. PubMed DOI PMC

Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4:1025. PubMed DOI

Gelžinský J, Mayer O Jr, Seidlerová J, Mateřánková M, Mareš Š, Kordíková V, et al. Soluble receptor for advanced glycation end-products independently influences individual age-dependent increase of arterial stiffness. Hypertens Res. 2020;43:111–20. PubMed DOI

Mayer O, Seidlerova J, Filipovsky J, Vagovicova P, Wohlfahrt P, Cifkova R, et al. Soluble receptor for advanced glycation end products and increased aortic stiffness in the general population. Hypertens Res. 2016;39:266–71. PubMed DOI

McNulty M, Mahmud A, Feely J. Advanced glycation end-products and arterial stiffness in hypertension. Am J Hypertens. 2007;20:242–7. PubMed DOI

Semba RD, Najjar SS, Sun K, Lakatta EG, Ferrucci L. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens. 2009;22:74–9. PubMed DOI

Dimitriadis K, Tsioufis C, Kasiakogias A, Miliou A, Poulakis M, Kintis K, et al. Soluble receptor for advanced glycation end-product levels are related to albuminuria and arterial stiffness in essential hypertension. Nutr Metab Cardiovasc Dis. 2013;23:382–8. PubMed DOI

Meerwaldt R, Graaff R, Oomen PHN, Links TP, Jager JJ, Alderson NL, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47:1324–30. PubMed DOI

Prasad K. Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases? Mol Cell Biochem. 2019;451:139–44. PubMed DOI

Cifkova R, Skodova Z, Bruthans J, Adamkova V, Jozifova M, Galovcova M, et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA Czech post-Monica Atherosclerosis. 2010;211:676–81. PubMed

Wohlfahrt P, Cifkova R, Krajcoviechova A, Sulc P, Bruthans J, Linhart A, et al. Comparison of three office blood pressure measurement techniques and their effect on hypertension prevalence in the general population. J Hypertens. 2020;38:656–62. PubMed DOI

Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588–605. PubMed DOI

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12. PubMed DOI PMC

Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;2016:207–74. DOI

Mayer O, Gelžinský J, Seidlerová J, Mateřánková M, Mareš Š, Svobodová V, et al. The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker? J Hum Hypertens. 2020. https://doi.org/10.1038/s41371-020-0327-3 . [Epub ahead of print].

Mac-Way F, Couture V, Utescu MS, Ignace S, De Serres SA, Loignon RC, et al. Advanced glycation end products, aortic stiffness, and wave reflection in peritoneal dialysis as compared to hemodialysis. Int Urol Nephrol. 2014;46:817–24. PubMed DOI

Ueno H, Koyama H, Tanaka S, Fukumoto S, Shinohara K, Shoji T, et al. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism. 2008;57:1452–57. PubMed DOI

Llauradó G, Ceperuelo-Mallafré V, Vilardell C, Simó R, Gil P, Cano A, et al. Advanced glycation end products are associated with arterial stiffness in type 1 diabetes. J Endocrinol. 2014;221:405–13. PubMed DOI

Ageev FT, Vitsenia MV, Smirnova MD, Mihailov GV.The relationship between level of end-products of tissue glycation and pulse wave velocity in non-diabetic patients with cardiovascular disease. Kardiologiia. 2015;55:63–7. PubMed DOI

Liu CY, Huang QF, Cheng YB, Guo QH, Chen Q, Li Y, et al. A Comparative Study on Skin and Plasma Advanced Glycation End Products and Their Associations with Arterial Stiffness. Pulse (Basel). 2017;4:208–18. DOI

van Eupen MG, Schram MT, van Sloten TT, Scheijen J, Sep SJ, van der Kallen CJ, et al. Skin Autofluorescence and Pentosidine Are Associated With Aortic Stiffening: the Maastricht Study. Hypertension. 2016;68:956–63. PubMed DOI

Stevens JW, Khunti K, Harvey R, Johnson M, Preston L, Woods HB, et al. Preventing the progression to type 2 diabetes mellitus in adults at high risk: a systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions. Diabetes Res Clin Pr. 2015;107:320–31. DOI

Ahmed N. Advanced glycation endproducts–role in pathology of diabetic complications. Diabetes Res Clin Pr. 2005;67:3–21. DOI

Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003. PubMed DOI